LifeMD (NASDAQ:LFMD) Issues Quarterly Earnings Results

Key Points

• LifeMD reported an adjusted loss of $0.11 per share, better than analysts’ expected $0.14 loss, but quarterly revenue of $44.6 million fell short of the $48.8 million consensus estimate.
• The company cut its 2026 revenue outlook to $188 million–$191 million from $205.5 million–$212.5 million and expects an adjusted EBITDA loss of $10.6 million–$12.6 million.
• LifeMD finalized arrangements to fulfill branded GLP-1 prescriptions from Eli Lilly and Novo Nordisk through its pharmacy. Management also cited lower customer acquisition costs and growth opportunities from its AT&T collaboration.

LifeMD (NASDAQ:LFMD - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03, FiscalAI reports. The company had revenue of $44.63 million for the quarter, compared to analyst estimates of $48.80 million. LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%.

Here are the key takeaways from LifeMD's conference call:

• Third-quarter revenue was $44.6 million, below guidance of $48 million–$51 million and down about 7% year over year. LifeMD cut its 2026 revenue outlook to $188 million–$191 million from $205.5 million–$212.5 million and now expects an adjusted EBITDA loss of $10.6 million–$12.6 million.
• LifeMD finalized arrangements with Eli Lilly and Novo Nordisk to fulfill and ship branded GLP-1 medications through its pharmacy, potentially adding revenue and gross profit dollars from prescriptions it previously fulfilled through third parties. Management cautioned that gross margin percentage will decline as branded-drug revenue is reported on a gross basis.
• Management said customer acquisition cost fell 40% from its June peak, while the share of new Weight Management patients choosing multi-month plans rose from about 25% to 85%. Active subscribers were up 13% year over year and nearly flat sequentially despite a 34% quarter-over-quarter reduction in selling and marketing expense.
• The AT&T collaboration is live in 11 states, reaching about 29 million customers, with nationwide rollout expected in January; the company also plans to market its enterprise offering to employers. Management described these as lower-cost growth opportunities, but said they were not included in fourth-quarter guidance and will report traction as they scale.
• LifeMD ended the quarter with $21.9 million in cash and no debt, then closed a $12.5 million term loan to support working-capital needs. It is targeting a 25% reduction in operating expenses by the first quarter of 2027 and said it expects roughly 30% revenue and patient growth in 2027 on about the same fixed overhead.

LifeMD Stock Down 7.0%

Shares of LFMD traded down $0.12 during trading hours on Thursday, reaching $1.66. 1,629,100 shares of the company traded hands, compared to its average volume of 876,691. The stock has a fifty day simple moving average of $2.65 and a 200 day simple moving average of $3.59. LifeMD has a fifty-two week low of $1.60 and a fifty-two week high of $5.38.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Lake Street Capital set a $5.00 target price on LifeMD in a research report on Thursday, August 6th. Mizuho set a $7.00 price target on shares of LifeMD in a report on Thursday, August 6th. BTIG Research decreased their price objective on shares of LifeMD from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of LifeMD in a report on Monday, November 2nd. Finally, Zacks Research raised LifeMD from a "strong sell" rating to a "hold" rating in a research note on Monday, August 17th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, LifeMD has an average rating of "Moderate Buy" and a consensus target price of $7.57.

About LifeMD

LifeMD, Inc. is a direct-to-consumer telehealth company that provides virtual medical care, prescription treatments and related health services through its digital platform. The company connects patients with licensed health care providers for online consultations, ongoing care and, when clinically appropriate, prescription medications. Its services include virtual primary care and programs focused on areas such as weight management, men's health, women's health, dermatology and chronic-care support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.